Ketamine Infusions in Insurance Claims: Emerging Pain Management
Understanding ketamine infusion therapy, evidence for chronic pain, safety profile, regulatory status, and medication review strategy for insurers.
Published: 3 April 2026 | Updated: 3 April 2026
Why Ketamine Infusions Are Emerging in Your Claims
Ketamine infusions have emerged as an increasingly requested "innovative" pain treatment in your claims portfolio, particularly for claimants with intractable chronic pain, complex regional pain syndrome (CRPS), or pain refractory to conventional pharmacotherapy. The mechanism involves low-dose intravenous ketamine administered in repeated infusion sessions, proposed to modulate pain via N-methyl-D-aspartate (NMDA) receptor antagonism and neuroplasticity effects.
As an insurer, your leverage lies in understanding that ketamine infusion therapy for chronic pain remains investigational; evidence is emerging but limited; and regulatory status is ambiguous. This article provides practical knowledge of ketamine mechanisms, evidence base, safety considerations, and triggers for medication review before funding decisions.
Ketamine Pharmacology and Mechanisms of Action
Ketamine is a dissociative anaesthetic that has been used clinically for decades at higher doses for anaesthesia and sedation. At sub-anaesthetic doses (0.5 to 1 mg/kg IV), ketamine produces analgesic effects through NMDA receptor antagonism, blockade of monoamine reuptake, and activation of opioid receptors. Proposed mechanisms for chronic pain include modulation of central sensitisation, reduction of pain processing in the dorsal horn, and possible neuroplasticity effects that reduce pain perception.
The theoretical basis is compelling, but clinical translation to chronic pain management remains incompletely understood. Unlike established pain medications (duloxetine, gabapentin), ketamine's effects on chronic pain are not yet mechanistically fully elucidated.
Evidence Base for Chronic Pain: What the Literature Shows
Evidence for ketamine infusions in chronic pain is accumulating but remains limited. Small randomised controlled trials and observational studies suggest ketamine infusions may provide pain relief in complex regional pain syndrome (CRPS), fibromyalgia, and chronic pain refractory to conventional agents. However, study sizes are typically small (20 to 60 participants), follow-up periods are short (weeks to months), and many studies lack control groups, making definitive efficacy assessment difficult.
A meta-analysis of ketamine for chronic pain noted moderate evidence for CRPS and fibromyalgia, but heterogeneity across studies is substantial. For neuropathic pain and general chronic pain, evidence is weaker. Importantly, few studies directly compare ketamine to established therapies like duloxetine or comprehensive pain management programmes.
Treatment Protocols and Dosing
Common ketamine infusion protocols involve low-dose IV ketamine (0.5 to 1 mg/kg) administered weekly or twice-weekly for a series of 6 to 10 infusions, with optional maintenance infusions. Sessions typically last 30 to 60 minutes. Dosing varies substantially across providers; standardised protocols remain lacking, creating variability in what claimants receive across different clinics.
This variability is a red flag for your claims: without standardised protocols, efficacy and safety data become difficult to compare. Claimants may receive wildly different regimens from different providers, making outcomes assessment problematic.
Efficacy and Outcomes: Duration and Durability
Reports of ketamine infusion efficacy in chronic pain show initial pain relief in some claimants, but durability is inconsistent. Pain improvements often emerge within days to weeks but may attenuate over months, requiring maintenance infusions to sustain effect. Some claimants report no effect; others report substantial pain reduction. The wide variability in response suggests individual factors (pain aetiology, central sensitisation status, psychological factors) influence outcomes substantially.
For your claims, the critical question is: does ketamine infusion therapy produce durable functional improvement in pain, mobility, or work capacity? Transient pain relief that doesn't translate to functional recovery may not justify treatment cost.
Safety Profile and Adverse Effects
At sub-anaesthetic doses, ketamine produces dissociation, dizziness, cognitive dulling, and psychotomimetic effects (perceptual disturbance, derealization). These effects are typically transient (minutes to hours post-infusion) but can be distressing. Long-term cognitive effects from repeated sub-anaesthetic infusions are not well-characterised.
Additionally, ketamine has abuse potential; chronic ketamine use is associated with cystitis, neuropsychiatric effects, and hepatotoxicity at higher doses. While therapeutic infusion protocols use lower doses than recreational use, repeated exposure creates some dependence risk and should not be dismissed.
| Adverse Effect | Timing and Frequency | Clinical Significance | Management |
|---|---|---|---|
| Dissociation, dizziness | During infusion and 1-4 hours post | Usually self-limited; impairs driving/work immediately post-infusion | Requires supervised setting; post-infusion monitoring; claimant cannot return to work same day |
| Psychotomimetic effects (perceptual disturbance) | During infusion; usually resolves within hours | Can be distressing; concerning in claimants with psychiatric history | Pre-treatment psychological screening; benzodiazepine pre-medication possible; contraindication if psychosis history |
| Cognitive dulling | Hours to days post-infusion | Impairs work capacity and cognition transiently | Monitor cognitive function; avoid safety-sensitive work post-infusion |
| Hypertension, tachycardia | During infusion | Usually mild and transient; risk in cardiac disease | Baseline cardiac assessment; monitor BP/HR during infusion |
| Abuse potential, dependence | Chronic risk with repeated exposure | Some reports of claimants seeking repeated infusions; psychological dependence risk | Structured protocol limiting number of infusions; psychological screening and support |
When to Refer for a Medication Review
Ketamine infusion therapy requests in your claims warrant careful medication review:
- Initial ketamine infusion request; assess indication appropriateness, evidence basis, and whether conventional evidence-based therapies have been exhausted.
- Verification that claimant meets diagnostic criteria for CRPS or other indication with some evidence support.
- Assessment of prior therapy trials: has claimant completed adequate trials of duloxetine, gabapentin, pregabalin, physical therapy, and psychological therapy?
- Clarification of proposed protocol: number of infusions planned, frequency, dosing, and expected duration of therapy.
- Safety screening: psychiatric history, cardiac disease, substance use history that might contraindicate ketamine.
- Outcome documentation: if ketamine initiated, functional improvement must be documented within 8 to 12 weeks; absence of functional benefit should trigger cessation.
- Cost assessment: ketamine infusions are expensive (typically AUD 300 to 1000+ per infusion); cost-benefit analysis important before funding approval.
Medication Review Workflow: Ketamine Infusions
Step 1: Indication and Diagnostic Verification Pharmacist confirms diagnosis (CRPS vs. fibromyalgia vs. other chronic pain); assesses whether evidence base supports ketamine for specific indication.
Step 2: Prior Therapy Assessment Document prior trials of established pain medications (duloxetine, gabapentin, pregabalin); verify psychological therapy and physical rehabilitation attempts.
Step 3: Safety Screening Assess psychiatric history, cardiac status, substance use history; identify contraindications to ketamine therapy.
Step 4: Baseline Functional Documentation Before ketamine initiation, document pain scores, functional capacity (mobility, work status, activities of daily living).
Step 5: Post-Treatment Outcome Assessment After 6 to 8 infusions (typically 6 to 8 weeks), assess whether ketamine has produced measurable pain reduction and functional improvement; determine whether continued infusions justified.
Ketamine and Return-to-Work
Ketamine's dissociative effects immediately post-infusion make same-day return to work unsafe, particularly for safety-sensitive occupations. Claimants require supervised transport home post-infusion and should not operate vehicles or machinery for several hours. This creates practical constraints on work return planning: claimants on active ketamine infusion protocols cannot maintain regular employment requiring daily attendance and safety sensitivity.
Conversely, if ketamine infusion therapy produces substantial pain relief enabling functional recovery, return-to-work may become feasible once infusion series is complete.
Cost-Benefit and Funding Considerations
Ketamine infusions are expensive, typically costing AUD 300 to 1000+ per infusion. A standard series of 6 to 10 infusions represents a direct cost of AUD 2,000 to 10,000 or more, plus ongoing maintenance infusions if required. For your organisation, this represents substantial cost for investigational therapy with emerging evidence.
A critical funding question: is the evidence strong enough and the functional benefit documented enough to justify this cost, when established therapies with stronger evidence bases (duloxetine, gabapentin, comprehensive pain management) are less expensive?
Alternative Approaches and Sequencing in Your Claims
Before considering ketamine infusions, claimants should have completed adequate trials of evidence-based pain medications and interdisciplinary pain management including physical therapy, psychological therapy (CBT, pain neuroscience education), and functional rehabilitation. Ketamine should not be first-line or second-line therapy; it should be considered only after established approaches have been optimised.
Additionally, claimants with psychological comorbidities (depression, anxiety, PTSD) should receive concurrent psychological treatment alongside ketamine, as some ketamine effects on pain may be mediated through mood improvement.
Summary and Key Takeaways
Ketamine infusions in your claims represent investigational therapy with emerging evidence that warrants careful scrutiny before funding:
- Evidence for ketamine infusions in chronic pain is emerging but limited; strongest evidence exists for CRPS; weaker for other chronic pain indications.
- Ketamine is not standard of care; it is investigational therapy that should be considered only after established pain medications and therapies have been optimised.
- Dissociative effects post-infusion impair work capacity; claimants cannot return to work same-day; this affects return-to-work planning.
- Functional improvement must be documented within 6 to 8 infusions; absence of functional benefit should trigger cessation.
- Cost is substantial; cost-benefit analysis should compare ketamine cost to evidence-based alternatives before funding approval.
- A pharmacist-led medication review assesses indication appropriateness, safety, prior therapy trials, and functional outcomes; supporting informed insurer decisions about ketamine funding.
Should you fund ketamine infusions in your claims?
IMM's medication review specialists assess ketamine infusion requests for indication appropriateness, evidence basis, safety profile, and cost-benefit. We help clarify whether ketamine represents justified therapy after established approaches have been optimised, enabling informed insurer decisions that balance innovation with evidence and cost-effectiveness.
Request a Medication Review
